More about

Adalimumab

News
December 20, 2021
2 min read
Save

Coherus’ Yusimry nabs FDA approval as seventh Humira biosimilar in cramped market

Coherus’ Yusimry nabs FDA approval as seventh Humira biosimilar in cramped market

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

News
November 11, 2021
2 min read
Save

Initial choice of biologic may affect persistence of therapy in IBD

Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.

News
October 29, 2021
1 min read
Save

Top in rheumatology: FDA approval of Cyltezo, arthritis burden in US

Top in rheumatology: FDA approval of Cyltezo, arthritis burden in US

The FDA recently approved Cyltezo as the first interchangeable biosimilar for certain inflammatory diseases, allowing prescribers to substitute it for Humira without a prescription change. It was the top story in rheumatology last week.

News
October 26, 2021
4 min watch
Save

VIDEO: Indirect comparison yields similar risk, benefit profiles among UC treatment

VIDEO: Indirect comparison yields similar risk, benefit profiles among UC treatment

LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs. adalimumab and a comparable profile for ozanimod vs. vedolizumab.

News
September 13, 2021
3 min read
Save

ORAL Strategy: Tofacitinib effective in RA subset 'irrespective' of concomitant MTX

ORAL Strategy: Tofacitinib effective in RA subset 'irrespective' of concomitant MTX

Patients with rheumatoid arthritis who achieved greater response with tofacitinib do so regardless of whether methotrexate was added to therapy or not, according to data published in Arthritis Research & Therapy.

News
August 19, 2021
1 min read
Save

Adalimumab biosimilar is safe, effective in patients with Crohn’s

Adalimumab biosimilar is safe, effective in patients with Crohn’s

Adalimumab biosimilar BI 695501 demonstrated similar safety and efficacy compared with adalimumab reference product among patients with Crohn’s disease, according to research published in the Lancet Gastroenterology and Hepatology.

News
July 29, 2021
2 min read
Save

Adalimumab may be efficacious, safe treatment for children with ulcerative colitis

Adalimumab may be efficacious, safe treatment for children with ulcerative colitis

Adalimumab was an efficacious and safe treatment option for pediatric patients with moderate to severe ulcerative colitis, according to findings published in Lancet Gastroenteroly and Hepatology.

News
July 07, 2021
2 min read
Save

Methotrexate boosts psoriatic arthritis remission rates for both adalimumab, infliximab

Methotrexate boosts psoriatic arthritis remission rates for both adalimumab, infliximab

Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with psoriatic arthritis, versus TNF-inhibitor monotherapy, according to data published in the Annals of the Rheumatic Diseases.

News
June 25, 2021
1 min read
Save

Top in rheumatology: Humira biosimilars, refractory Lyme arthritis

Top in rheumatology: Humira biosimilars, refractory Lyme arthritis

Amid a lawsuit battle concerning a Humira biosimilar product between AbbVie and Alvotech, experts predict that the market will explode as greater competition begins to erode Humira’s profits.

News
June 18, 2021
7 min read
Save

Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close

Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close

On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it alleges is a “minefield” of “invalid” patents surrounding what is arguably the pharma giant’s most prized possession: Humira.

View more